e-learning
resources
European Respiratory Review
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?
Harari Sergio, Humbert Marc, Blasi Francesco, Collard Harold R., Matucci-Cerinic Marco, Simonneau Gerald, Vancheri Carlo, Wells Athol U., Cottin Vincent
Source:
Eur Respir Rev 2015; 24: 375-377
Journal Issue:
September
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Harari Sergio, Humbert Marc, Blasi Francesco, Collard Harold R., Matucci-Cerinic Marco, Simonneau Gerald, Vancheri Carlo, Wells Athol U., Cottin Vincent. Rare pulmonary diseases and orphan drugs: where do we stand and where are we going to?. Eur Respir Rev 2015; 24: 375-377
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Bronchiectasis in patients with alpha1-antitrypsin deficiency: prevalence and characteristics
Role of HGF in the healthy and injured lung
Pirfenidone in idiopathic pulmonary fibrosis (IPF): Early Spanish experience with the European Named patient program (NPP)
Related content which might interest you:
Rare pulmonary disease and orphan drugs: a path to the future
Source: Eur Respir Rev, 28 (153) 190115; 10.1183/16000617.0115-2019
Year: 2019
Rare pulmonary diseases: a common fight
Source: Eur Respir Rev, 26 (145) 170059; 10.1183/16000617.0059-2017
Year: 2017
What’s new in interstitial lung diseases in children?
Source: Virtual Congress 2021 – Paediatric year in review
Year: 2021
Bronchiectasis: how to be an orphan with many parents?
Source: Eur Respir J 2016; 47: 10-13
Year: 2016
Development of medicines for rare diseases: where are the problems?
Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases"
Year: 2014
Cleaning agents: how they look like and how might they cause respiratory harm?
Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health?
Year: 2018
Pulmonary rehabilitation, where do we come from and where do we go to?
Source: Annual Congress 2009 - PG20 State of the art in pulmonary rehabilitation
Year: 2009
Chronic diseases like asthma and COPD: do they truly exist?
Source: Eur Respir J 2016; 47: 359-361
Year: 2016
Sub-glottic Stenosis: An orphan tracheopathy – a great asthma mimic!
Source: Virtual Congress 2021 – Comorbidities in airway obstructive diseases
Year: 2021
Cleaning agents and asthma: what does the epidemiology really tell us?
Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health?
Year: 2018
Thrombo-embolic pulmonary hypertension: which treatment should we choose? / Hypertension pulmonaire thrombo-embolique: quel traitement choisir ?
Source: International Congress 2018 – French Programme 2018: Part II
Year: 2018
Rare and 'orphan' lung diseases
Source: Breathe 2008; 5: 101-104
Year: 2008
What's it like to live with idiopathic pulmonary fibrosis? Ask the experts
Source: Eur Respir J 2016; 47:1324-1326
Year: 2016
Antifungals in pulmonary infections: to whom, when and how?
Source: Eur Respir Monogr 2017; 75: 159-184
Year: 2017
Treating asthma in developing countries: is this a question of money?
Source: Eur Respir J 2005; 26: Suppl. 49, 274s
Year: 2005
Chronic post-embolic pulmonary hypertension: a new target for medical therapies?},
Source: Eur Respir Rev 2013; 22: 258-264
Year: 2013
Toward better management of rare and orphan pulmonary diseases
Source: Eur Respir J 2016; 47:1334-1335
Year: 2016
Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?},
Source: Eur Respir Rev 2013; 22: 217-226
Year: 2013
Genetic variation and common diseases. Where are we? Where to go?
Source: Research Seminar 2009 - Post Genome Respiratory Epidemiology II - An interdisciplinary challenge
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept